Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial

Ronald (Ron) Rosenfeld, Raymond L. Hintz, Ann J. Johanson, Jo Anne Brasel, Stephen Burstein, Steven D. Chernausek, Teresa Clabots, James Frane, Ronald W. Gotlin, Joyce Kuntze, Barbara M. Lippe, Patrick C. Mahoney, Wayne V. Moore, Maria I. New, Paul Saenger, Elizabeth Stoner, Virginia Sybert

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (-0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.

Original languageEnglish (US)
Pages (from-to)936-943
Number of pages8
JournalThe Journal of Pediatrics
Volume109
Issue number6
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Oxandrolone
Turner Syndrome
Growth
Therapeutics
Bone and Bones
somatrem

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Rosenfeld, R. R., Hintz, R. L., Johanson, A. J., Brasel, J. A., Burstein, S., Chernausek, S. D., ... Sybert, V. (1986). Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial. The Journal of Pediatrics, 109(6), 936-943. https://doi.org/10.1016/S0022-3476(86)80272-4

Methionyl human growth hormone and oxandrolone in Turner syndrome : Preliminary results of a prospective randomized trial. / Rosenfeld, Ronald (Ron); Hintz, Raymond L.; Johanson, Ann J.; Brasel, Jo Anne; Burstein, Stephen; Chernausek, Steven D.; Clabots, Teresa; Frane, James; Gotlin, Ronald W.; Kuntze, Joyce; Lippe, Barbara M.; Mahoney, Patrick C.; Moore, Wayne V.; New, Maria I.; Saenger, Paul; Stoner, Elizabeth; Sybert, Virginia.

In: The Journal of Pediatrics, Vol. 109, No. 6, 1986, p. 936-943.

Research output: Contribution to journalArticle

Rosenfeld, RR, Hintz, RL, Johanson, AJ, Brasel, JA, Burstein, S, Chernausek, SD, Clabots, T, Frane, J, Gotlin, RW, Kuntze, J, Lippe, BM, Mahoney, PC, Moore, WV, New, MI, Saenger, P, Stoner, E & Sybert, V 1986, 'Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial', The Journal of Pediatrics, vol. 109, no. 6, pp. 936-943. https://doi.org/10.1016/S0022-3476(86)80272-4
Rosenfeld, Ronald (Ron) ; Hintz, Raymond L. ; Johanson, Ann J. ; Brasel, Jo Anne ; Burstein, Stephen ; Chernausek, Steven D. ; Clabots, Teresa ; Frane, James ; Gotlin, Ronald W. ; Kuntze, Joyce ; Lippe, Barbara M. ; Mahoney, Patrick C. ; Moore, Wayne V. ; New, Maria I. ; Saenger, Paul ; Stoner, Elizabeth ; Sybert, Virginia. / Methionyl human growth hormone and oxandrolone in Turner syndrome : Preliminary results of a prospective randomized trial. In: The Journal of Pediatrics. 1986 ; Vol. 109, No. 6. pp. 936-943.
@article{3adb0e614e7b4f38ac90daaa79d97fc4,
title = "Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial",
abstract = "Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (-0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.",
author = "Rosenfeld, {Ronald (Ron)} and Hintz, {Raymond L.} and Johanson, {Ann J.} and Brasel, {Jo Anne} and Stephen Burstein and Chernausek, {Steven D.} and Teresa Clabots and James Frane and Gotlin, {Ronald W.} and Joyce Kuntze and Lippe, {Barbara M.} and Mahoney, {Patrick C.} and Moore, {Wayne V.} and New, {Maria I.} and Paul Saenger and Elizabeth Stoner and Virginia Sybert",
year = "1986",
doi = "10.1016/S0022-3476(86)80272-4",
language = "English (US)",
volume = "109",
pages = "936--943",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Methionyl human growth hormone and oxandrolone in Turner syndrome

T2 - Preliminary results of a prospective randomized trial

AU - Rosenfeld, Ronald (Ron)

AU - Hintz, Raymond L.

AU - Johanson, Ann J.

AU - Brasel, Jo Anne

AU - Burstein, Stephen

AU - Chernausek, Steven D.

AU - Clabots, Teresa

AU - Frane, James

AU - Gotlin, Ronald W.

AU - Kuntze, Joyce

AU - Lippe, Barbara M.

AU - Mahoney, Patrick C.

AU - Moore, Wayne V.

AU - New, Maria I.

AU - Saenger, Paul

AU - Stoner, Elizabeth

AU - Sybert, Virginia

PY - 1986

Y1 - 1986

N2 - Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (-0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.

AB - Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (-0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.

UR - http://www.scopus.com/inward/record.url?scp=0022979669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022979669&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(86)80272-4

DO - 10.1016/S0022-3476(86)80272-4

M3 - Article

C2 - 3537249

AN - SCOPUS:0022979669

VL - 109

SP - 936

EP - 943

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -